_	4 1 6	•	• •	•		• 1		•	
)	npataral tap an	OTTOPYTOM O	it evetomot	O POWIOWS	and	AVIDANA	monr	NINO	٤
/	protocol for an	UVELVIEW U	JI SVSICIIIAL	C I CVICWS	anu	cviuciice	11114171	ниν	4
_	Protocor 101 W	0 1 02 120 11 0	, , , , , , , , , , , , , , , , , , , ,		*****			/ <u>-</u>	

- 4 **Authors**: Qingcong Mo^{a,#}, Siqi Xu^{b,#}, Fangfei Hu^a, Xiaoyan Zheng^{b,*}
- 5 *Qingcong Mo and Siqi Xu contributed equally to this work

7 Affiliations:

3

6

10

11

17

- 8 aSchool of Traditional Chinese Medicine, Southern Medical University, Guangzhou, China.
- ^bSchool of Rehabilitation Sciences, Southern Medical University, Guangzhou, China.

*Corresponding authors:

- 12 Full name: Xiaoyan Zheng
- Mailing address: School of Rehabilitation Sciences, Southern Medical University, 1023-1063
- 14 Shatai South Road, Guangzhou, China
- E-mail address: zxy18825147762@smu.edu.cn
- 16 Phone: (+86) 18825147762

ABSTRACT

Introduction

Kinesio taping (KT) has been extensively applied in the management of musculoskeletal disorders. Although plentiful systematic reviews (SRs) have evaluated its efficacy, there are no convincing conclusions due to disperse and inconclusive results, and its clinical relevance remains unclear. Hence, there is a need to summarise all the SRs for the comprehensive and consistent evidence. This overview aims to appraise the overall effectiveness of KT in musculoskeletal disorders, and provide evidence maps to visualise the findings.

Method and analysis

Electronic databases (Cochrane Database of Systematic Reviews, MEDLINE, Embase, Epistemonikos, PEDro, Scopus, ISI Web of Science) and reference lists will be searched from inception to September 2024 for the SRs of randomised controlled trials (RCTs). The SRs involving comparisons of the effectiveness between single or adjunctive KT and other interventions for patients with musculoskeletal disorders will be included. The primary and additional outcome to be considered will be the core outcome set, and the patient-reported outcome measure and patient-important outcome, respectively. Two reviewers will independently screen and select studies, extract the data, and evaluate the reporting and methodological quality of eligible SRs as well as the risk of bias of included RCTs. For the SRs without meta-analysis, we will collate the number of RCTs that showed any differences in outcomes. For the SRs with meta-analysis, we will provide the original summary of evidence (e.g., pooled effects and heterogeneity) for outcomes with an evaluation of missing results and clinical relevance. The certainty of each outcome will be measured, and user-friendly maps of

40 findings will be presented graphically.

Ethics and dissemination

41

47

- Formal ethical approval for this study is not required, since the data will be only collected from
- published literature in public databases. The results will be disseminated in the peer-reviewed
- academic journal, and relevant datasets will be preserved in the online repository.

45 **PROSPERO** registration number

46 CRD42024517528

Strengths and limitations of this study

- This study will be carried out and reported following the Cochrane Collaboration
- Handbook for Overviews of Reviews and the Preferred Reporting items for Overviews of
- Reviews statement.
- This study will only include systematic reviews with and without meta-analysis of
- 52 randomised controlled trials.
- This study will evaluate the reporting and methodological quality of systematic reviews,
- examine the risk of bias and degree of overlap of randomised controlled trials, and manage
- discordant results by selecting the most representative research.
- This study will perform the assessment of missing results and certainty for the evidence,
- 57 interpret the clinical relevance between effects and outcomes, and provide evidence maps
- of comprehensive and systematic findings.
- This study may not be up-to-date as newly published randomised controlled trials will not
- be included, and ultimate conclusions will probably be limited by clinical heterogeneity
- due to variations in dose or application method of kinesio taping.

INTRODUCTION

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

Musculoskeletal disorders are a major and serious healthcare issue.[1] It consist of a group of more than 150 different and irreversible diseases/conditions that affect the locomotor system (including muscles, bones, joints and adjacent connective tissues).[2,3] Among them, the most prevalent conditions are low back pain, fractures, osteoarthritis, other injuries, neck pain, amputation, and rheumatoid arthritis.[4,5] Globally, musculoskeletal disorders are common among adolescents to the elderly, and the highest burden is expected to be concentrated in people aged 50-54 years.[6,7] Over the past few decades, with the growth and aging of population, musculoskeletal disorders have become increasingly serious.[4,5] Estimates of the prevalence of musculoskeletal disorders suggested substantial increases in global cases and years of life lived with disability, affecting approximately 1.71 billion individuals.[4,5] Patients with musculoskeletal disorders may suffer from various health-related negative outcomes, involving problems in pain intensity, functional status, psychological state, quality of life, and more. [5,8,9] The consequences of these problems may lead to work-related disability while reducing productivity and increasing direct and indirect economic costs.[3,8,10,11] In addition, the risk of developing other noncommunicable diseases, especially cardiovascular diseases, is higher in people with musculoskeletal disorders than in those without them.[12] As a typical feature of musculoskeletal disorders, co-occurring persistent pain in different body regions beyond the primary pain may have implications for patients' prognosis, treatment method, and outcome. [13,14] Hence, research on musculoskeletal disorders requires more attention, although they mainly lead to disability rather than death.[15,16]

In an attempt to meet the massive demand of rehabilitation services,[4,5] active management for musculoskeletal disorders is needed.[16-18] Currently, non-invasive treatments have a significant impact on the treatment of various musculoskeletal disorders.[15] Among them, kinesio taping (KT), a form of taping technique, has been extensively utilized across countries/regions for many years to support sports science and rehabilitation.[19] The application of KT in musculoskeletal disorders is widespread.[20]

Description of the intervention

KT is an elastic therapeutic taping tool consisting mainly of cotton, originally created and introduced by Dr. Kenso Kase in the 1970s.[21] It is lightweight, waterproof, breathable and available in a wide range of colours, types, lengths, widths, textures and techniques.[21] Following assessment and instruction from healthcare professionals, KT can be directly fixed to the target tissue with different combinations of cuts (e.g., Y, I, X tape), tensions (e.g., percentage of stretch), and directions (e.g., muscle insertion to origin).[21] Wearing of KT may maintain the effect for 3 to 5 days, ideally following the 24 hours application rule based on the skin condition.[22]

Over the past decade, the popularity of KT is increasing worldwide given the promising benefits suggested by plentiful clinical studies.[19,22] KT assists users with musculoskeletal disorders in relieving pain intensity,[23] modulating extremity function,[23] and improving proprioception,[24] stability,[25] range of motion,[26] and quality of life.[27] These therapeutic effects are probably supported by the mechanisms of KT that it increases the subcutaneous space, stimulates skin sensory receptors, and provides support for mechanical behaviour and

biomechanics of the skin.[21,28-30] Applying different tensions of it on the skin may reduce partial pressure, accelerate blood and lymphatic circulation, and increase muscle temperature, thus promoting regional microcirculation.[21,31,32] People with a psychologically anticipated response to the effect of KT are likely to induce greater placebo effects, thus contributing to enhanced muscle function.[33-35] Although there is some evidence to support the theory of KT, its precise working mechanism remains unclear and many studies showed conflicting therapeutic results.[36] Consequently, the inconclusive findings of KT have resulted in a longstanding debate regarding the effectiveness and clinical relevance.

Significance of conducting the review

Due to substantial controversy over the results of KT reported in the primary studies, researchers have carried out plentiful systematic reviews (SRs) with and without meta-analysis to evaluate the clinical effectiveness of KT.[37-40] However, the inconclusive evidence of musculoskeletal disorders was presented in the SRs as well, involving elbow,[41,42] shoulder,[43-45] back,[46-48] knee,[49-51] and spine.[52]

Meanwhile, the majority of SRs may not examine the clinical relevance of KT. The minimal clinically important difference (MCID) is considered to be the smallest change that appears to have a benefit implication for patient's treatment outcome.[53,54] The application of MCID assists in establishing numerical thresholds for clinical research that only identified statistically significant impacts of intervention with little or unknown clinical relevance for patients.[55-57] Nevertheless, Embry and Piccirillo retrieved the journal and found that large percentage of randomised controlled trials (RCTs) (69%) did not define the MCID or mention

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

it.[58] The lack of additional confirmation regarding the clinical relevance of KT presumably added difficulties to clinical interpretation of its effects. As the number of SRs increased to date, the existing evidence of KT probably created gaps between research and practice, as well as variations in clinical opinions among healthcare providers.[59,60] Hence, there is a need to summarise and assess the overall effectiveness of KT in musculoskeletal disorders from all the SRs. Overview of SRs, a method of reviewing multiple SRs, is capable of collating broad information, synthesizing diverse findings, and presenting a well-organized and detailed summary of evidence. [61,62] This evidence-based method is frequently applied to develop a unified perspective when there are conflicting conclusions on a specific topic at the level of the SRs due to different selection methods, potential sources of heterogeneity and risk of bias, and variable reporting and methodological quality.[61,62] In addition, evidence mapping is a effective and evolving methodological tool for integrating and presenting evidence through user-friendly visual graphics.[63,64] Cupler and colleagues have provided an evidence map of four types of taping (KT, Rigid taping, McConnell taping and Mulligan taping) for musculoskeletal conditions.[65] However, the limitation of the study is that the evidence maps were based on the included RCTs and did not clarify the relationship between the outcomes and the contradictory findings of the SRs. Application of evidence mapping for overview of SRs plays a complementary role in conveniently identifying research gaps and rapidly disseminating knowledge.[63,64,66,67] To date, no studies have evaluated the existing evidence on the effectiveness and clinical relevance of KT in musculoskeletal disorders from the SRs. To fill the gap of knowledge, we

will conduct an overview of SRs and evidence mapping to inform evidence-based clinical practice and support healthcare decision-making. The relevant findings obtained by this study will be expected to benefit researchers, physiotherapists, stakeholders, and particularly multiple patients at various stages of musculoskeletal rehabilitation.

Objective and research question

This study aims to appraise the overall effectiveness of KT in musculoskeletal disorders, and provide evidence maps to visualise the findings. This study will examine the following research questions: (1) Is KT effective in patients diagnosed with musculoskeletal disorders? (2) What types of outcomes does KT demonstrate positive, no, or negative effects on?

METHODS AND ANALYSIS

Protocol and registration

This study is designed as an overview of SRs and evidence mapping. We have prospectively registered this protocol within the International Prospective Register of Systematic Reviews (PROSPERO, Registration number: CRD42024517528). The protocol has been presented in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols (PRISMA-P) statement (Supplementary File 1).[68] We will conduct the overview following the methodology of Cochrane Collaboration Handbook for Overviews of Reviews.[69]

Patient and public involvement

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

No patients or the public involved in this overview of SRs and evidence mapping. Eligibility criteria Types of studies Standard-compliant SRs with and without meta-analysis of RCTs will be considered for inclusion. The definition of systematic review and meta-analysis will be adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 2020 statement, [70] as follows: systematic review means to use explicit, systematic methods to collate and synthesise findings of studies that address a articulated question; meta-analysis is a statistical method for synthesising results when research effect estimates and their variances are available. If the SRs were published in other languages than English, or only searched one database, or no details of primary RCTs were provided, they will be excluded. Protocols of overview and SRs, scoping review and network meta-analysis will be excluded as well. Types of participants Guided by the International Classification of Diseases 11th revision (ICD-11),[71] we will include participants who have a diagnosis of musculoskeletal disorders. Eligible individuals will be included, regardless of their age, gender, and region. Additionally, we will exclude animals from participation. Types of interventions The SRs that evaluated the effectiveness of KT in musculoskeletal disorders will be considered

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

for inclusion. KT must be used as a core treatment method in the experimental group, either as monotherapy or combination therapy. The way of applying KT on the body must be related to the musculoskeletal system. It will not be limited by tension, direction, and regimen. Types of comparators No strict intervention limitations on the type of control group will be set, such as no treatment, standard of care, placebo control, medication therapy, rehabilitation, and other interventions (e.g., traditional Chinese medicine therapy, surgical treatment). KT as a treatment method will be excluded in this group. Types of outcome measures With the ability to lower the risk of heterogeneity, inconsistency, and outcome-reporting bias between trials, the core outcome set will be the primary outcome. [72] First, we will search specific musculoskeletal disorders related to KT usage in eligible SRs on the MEDLINE or the website (https://comet-initiative.org/). Then, we will select the most up-to-date (i.e., date approaching 2022-2024), credible (e.g., registered research, multi-round survey, more stakeholders included), and standard (e.g., reported more complete items in the checklist of Core Outcome Set-STAndards for Development)[73] core outcome set to consider any promising outcomes that must be relevant to patients. If partial musculoskeletal disorders are not assessed by the core outcome set, we plan to consider patient-reported outcome measures [74] and patient-important outcomes. [75] They are able to reflect patient perspectives on their symptoms, functional status, quality of life, and 216 more. The following additional outcomes will be considered: 1. Pain intensity, which measured by standard or specific scales (e.g., Numerical Rating Scale 217 (NRS), Visual Analogue Scale (VAS)). 218 219 2. Upper and lower limb function and/or disability status, which measured by standard or specific scales (e.g., Range of Motion (ROM), Disabilities of the Arm, Shoulder and Hand 220 (DASH), Victorian Institute of Sport Assessment-Patella Questionnaire (VISA-P), Roland-221 222 Morris Disability Questionnaire (RMDQ)). 3. Quality of life, which measured by standard or specific scales (e.g., Short-Form 36 Health 223 Survey Questionnaire (SF-36), EORTC Core Quality of Life questionnaire (EORTC QLQ-C30), 224 225 WHO Quality of Life Brief Questionnaire (WHOQOL-BREF)). 4. Disease-specific symptom, which measured by standard or specific scales (e.g., Grip Strength 226 (GS) for lateral epicondylitis). 227 228 **Search strategy and selection** 229 According to the Preferred Reporting Items for Systematic reviews and Meta-Analyses 230 literature search extension (PRISMA-S) guideline, [76] our search will be conducted in the 231 following electronic databases (Cochrane Database of Systematic Reviews, MEDLINE, 232 Embase, Epistemonikos, PEDro, Scopus, ISI Web of Science) from inception to September 233 234 2024. We will also perform a search to identify any registered yet unpublished SRs and grey literature in the PROSPERO and OpenGrey, respectively. In addition, we will hand-search the 235 reference lists of included SRs for any relevant cited SRs in Google Scholar. The search strategy 236 is developed involving the integration of MeSH terms, keywords and free text terms related to 237

KT: (kinesio taping OR kinesio tape OR kinesiotaping OR kinesiotap OR physiotape OR tape OR taping) AND (systematic review OR meta-analysis).

Two independent literature reviewers will screen titles and abstracts of the SRs output through the EndNote V.21 software to identify eligible articles. Then, the same reviewers will download the promising SRs and assessed them by full-text reading for final inclusion. Afterwards, applying Gwet's AC1 statistics and related 95% confidence interval (CI),[77] one reviewer will evaluate the agreement on study selection between two reviewers using R language V.4.3.2. Considering that application of the classification from Landis and Koch to Gwet's AC1 is inappropriate,[78] the inter-rater reliability will be cautiously explained. The Fisher's exact test will be performed to determine its statistical significance (P value). Any disagreement will be discussed or consulted the third reviewer for a consensus.

Data extraction

We will extract and cross-check data from the SRs in standardised tables based on predefined criteria, using an electronic form of Microsoft Excel 2019. All data must be related to KT only. Data concerning the basic information (first author's name, year of publication, country/region of the first author's affiliation, and number of the included primary RCTs), participants characteristic (number of participants and disease or condition), search strategy (number and names of databases searched and date range of search), type of comparison, outcome measurement, evidence assessment tool (risk of bias and certainty of evidence) and study conclusion (e.g., positive effect, no effect, negative effect) will be extracted. If we identified discrepant data of included same studies in different SRs, we plan to contact the corresponding

authors or to retrieve and follow the raw data of primary RCTs.

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

third reviewer.

If the SRs with meta-analysis analysed outcomes with more than one study, two reviewers will extract the analytical methods (fixed or random effects model), heterogeneity (Cochran's Q test P value and I-square statistic), pooled effects with 95% CI (mean difference (MD) or standardized mean difference (SMD) for continuous outcome; relative risk (RR) or odds ratio (OR) for binary outcome), direction (differences in favour of KT or control intervention), statistical significance (P value) and publication bias (at least 10 studies). If the follow-up data is available, we will extract them as well. To provide a complete summary of KT, we will use the Risk of Bias due to Missing Evidence (ROB-ME) tool to assess the meta-analysis results.[79] Briefly, three steps will be conducted following the tool: select meta-analyses related to outcome (step 1), determine which eligible studies have missing results (step 2), and consider potential for missing studies (step 3). Response options for the signal questions are categorised as 'yes', 'probably yes', 'probably no', 'no', 'no information' or 'not applicable'. Then, the results will be judged and interpreted as 'low risk of bias', 'some concerns' or 'high risk of bias'. Discrepancies considered potentially relevant by one reviewer will be discussed and, if needed, will be ultimately resolved by the

Managing the overlap between primary RCTs

As the number of SRs and updated SRs for KT increased to date, the identical or highly similar questions related to musculoskeletal disorders were probably answered.[80] To avoid double counting data from overlapped SRs, we will extract the information on characteristics of

primary RCTs separately (first author's name, year of publication, number of participants, type of comparison, pre- and post-intervention outcome measurement data with or without follow-up). After removing duplicated articles, we will combine the results into a table.

Based on the specific clinical question, a matrix of included primary RCTs in the SRs will be created and visualised to evaluate the amount of overlapping using the Graphical Representation of Overlap for OVErviews (GROOVE) tool.[81] When collating each outcome in the matrix, we will calculate the corrected covered area (CCA) regardless of any structural missing data. The CCA refers to a measurement for the degree of overlap and it will be interpreted as 'slight overlap' (0%–5%), 'moderate overlap' (6%–10%), 'high overlap' (11%–15%) or 'very high overlap' (>15%).[82]

Assessment of the reporting quality

Transparent and complete reporting of SRs supports to examine the feasibility of the methods and the reliability of the findings, thus bolstering evidence-based decision-making.[70,83] Two reviewers will separately evaluate the reporting quality of SRs with and without meta-analysis in accordance with the Synthesis without meta-analysis (SWiM) reporting guideline [83] and the PRISMA 2020 statement.[70] The SwiM guideline consists of 9 items and contains critical features of synthesis in the SRs without meta-analysis (e.g., the method of study category, data presentation, finding summary). The PRISMA checklist covers 27 items and is designed for SRs with meta-analysis that require detailed reporting in different sections (e.g., abstract, methods, results). Each item of the above checklist will be recorded and graded as 'completely reported', 'partially reported' or 'not reported' depending on whether the domains were clearly

documented. Then, we will calculate the compliance rate of the reporting in each of SRs to overview the overall reporting quality. Any differences of opinion will be resolved through discussion or determined by the third reviewer.

Assessment of the methodological quality and the risk of bias

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

The quality assessment of eligible SRs includes both the methodological quality and the risk of bias [84]. Two reviewers will independently assess them by the A Measurement Tool to Assess Systematic Reviews 2 (AMSTAR 2) [85] and Risk of Bias in Systematic reviews (ROBIS),[86] respectively. The AMSTAR 2 is a valid, reliable and user-friendly appraisal tool and most of the questions are binary. [87] After answering 16 original items (recommended critical domains are 2, 4, 7, 9, 11, 13, and 15), the overall methodological confidence of SRs will be judged as follows: 'high' (no or one non-critical weakness), 'moderate' (more than one non-critical weakness), 'low' (one critical flaw with or without non-critical weaknesses) or 'critically low' (more than one critical flaw with or without non-critical weaknesses). The ROBIS has rigorous methodology and is intended for assessing the level of bias within SRs through three phases: assess the relevance of SRs to outcome for KT (phase 1), identify concerns with the review process including study eligibility criteria, identification and selection of studies, data collection and study appraisal, synthesis and findings (phase 2), judge the risk of bias based on the concerns of each domain bias (phase 3).[86] The overall risk of bias will be rated as 'low', 'unclear' or 'high' according to the answers to signalling questions. In addition, we plan to re-evaluate the quality of each primary RCTs using the Cochrane

Risk of Bias assessment tool 2.0 (ROB 2.0),[88] if the SRs appraised the risk of bias by means

of other tool (e.g., Cochrane risk of bias tool, Jadad scale, PEDro scale). The ROB 2.0 consists of five bias domain originating from the randomisation process, deviations from intended interventions, missing outcome data, measurement of the outcome and selection of the reported result. Each domain will be required to rank the levels of evidence bias through a series of signalling questions to determine the judgement of overall risk of bias as 'low risk of bias', 'some concerns' or 'high risk of bias'. [88] Any differences will be settled through discussion or with the assistance of the third reviewer.

Strategies for data analysis

Within the SRs without meta-analysis, we will collate and summarise the number of RCTs that demonstrated any differences in the outcomes (i.e., statistically significant positive effect [direction of effect in favour of KT], statistically significant negative effect [direction of effect in favour of control intervention] and non-statistically significant effect). Statistical significance will be defined as a P value less than 0.05.[89] If the SRs incorporated comparisons that did not meet the eligible inclusion criteria, the corresponding RCTs will not be applicable for calculation. Using the vote counting method, we plan to present these RCTs as a percentage of all primary studies in the SRs along with 95% CI (Wilson interval).[90]

Regarding the SRs with meta-analysis, we will present the original summary of evidence (e.g., pooled effects, heterogeneity and direction) without carrying new meta-analyses for outcomes. However, when the same conceptual outcome that included interventions beyond KT (e.g., Rigid taping, McConnell taping, Mulligan taping) or was reported by different measurements (e.g., outcome of interest that should be calculated in MD but was calculated in

SMD), we plan to back-translate the primary data in the SRs to re-estimate the overall effects. For re-analysing the outcome data that incorporated other distinct types of KT, we will exclude these RCTs by examining the characteristics of primary studies. Then, the associated findings (i.e., pooled effects, heterogeneity and direction) will be extracted, and the publication bias (at least 10 RCTs) will be evaluated by the Egger's regression test. For the conversion of appropriate outcome measurements, we will present the binary outcomes as RR since the usage of OR in RCTs may exaggerate the effect size, leading to the misinterpretation in decision-making.[91,92] And the continuous outcomes will be presented as MD (same conceptual outcomes are measured on same scales) or SMD (same conceptual outcomes are measured on different scales).[93] In the above procedures, to maximise the retention of the authors' data processing methods, the re-estimation will be performed under the same settings corresponding to the SRs using the Review Manager V.5.4 software.

Strategies for managing concordant or discordant results

To provide the concordant evidence, we will organise the final results of KT (i.e., the proportion of RCTs that showed any effect and the overall pooled effects) from the SRs with and without meta-analysis into three categories (positive effect, no effect, and negative effect).[69] Table 1 provides detailed criteria for classification. A threshold of 80% SRs in the same classification will be set to determine the concordance of results [94] and the robustness of review findings will be discussed.[95]

Type of systematic review	Category of effect	Description
Systematic review without	Positive effect	The proportion of RCTs that showed
meta-analysis		statistically significant effect in favour of KT
		is the highest
	No effect	The proportion of RCTs that showed non-
		statistically significant effect is the highest
	Negative effect	The proportion of RCTs that showed
		statistically significant effect in favour of
		control intervention is the highest
Systematic review with	Positive effect	Continuous outcome: the statistically
meta-analysis		significant pooled effect size and associated
		95% CI is higher than 0 points (direction of
		effect in favour of KT)
		Dichotomous outcome: the statistically
		significant pooled effect size and associated
		95% CI is higher than 1 points (direction of
		effect in favour of KT)
	No effect	Continuous outcome: the associated 95% CI of
		pooled effect size crosses 0 points
		Dichotomous outcome: the associated 95% CI
		of pooled effect size crosses 1 points
	Negative effect	Continuous outcome: the statistically
	-	significant pooled effect size and associated
		95% CI is lower than 0 points (direction of
		effect in favour of control intervention)
		Dichotomous outcome: the statistically
		significant pooled effect size and associated
		95% CI is lower than 1 points (direction of
		effect in favour of control intervention)

Table 1 Effects classification criteria. CI, confidence interval; RCTs, randomised controlled trials; KT, kinesio taping.

When there are discordant results, methods of treatment involves examining and recording discordance, using adjunct decision rules or tools, and selecting the most representative study among the SRs.[96] In this management, we will consider varied standards for choosing the best SR, as the new meta-analyses will not be conducted and the utilization of Jadad algorithm

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

will be difficult to follow (i.e., limitations in operationalization and interpretation).[97] First, we will examine the resemblance of clinical question (e.g., moderate to very high overlap presented in CCA, similar scale used to combine effect size) across the SRs. Afterwards, the four-domain strategies (comprehensiveness, timeliness, riskiness, and reporting) will be applied to select the best SR that reported relatively trustworthy findings, as below: 1. Comprehensiveness: the SRs included the highest number of RCTs and participants. 2. Timeliness: the SRs conducted the most recent search date (i.e., date approaching 2022-2024) in the largest number of databases (e.g., MEDLINE, Embase, CINAHL). 3. Riskiness: the SRs that were evaluated as the highest methodological quality and the lowest risk of bias according to the AMSTAR 2 and ROBIS tool. 4. Reporting: the SRs reported the most complete items (number of items completely reported and partially reported) in the checklist of the SwiM guideline and the PRISMA 2020 statement. Assessment of the certainty of evidence Certainty of evidence supports the clinical and health decision-making process and its assessment is an essential part of overview of SRs according to the Cochrane guidelines.[98,99] For the SRs without meta-analysis, we will assess the overall quality of evidence following the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework.[100] Details of the application of the GRADE framework in the SRs without metaanalysis are in Supplementary File 2. If the SRs with meta-analysis used the GRADE methodology to determine the quality of evidence, we will extract and present the following information associated with outcomes: five

domains of downgrade (risk of bias, inconsistency, indirectness, imprecision and reporting bias), three domains of upgrade (large effects, dose response and opposing plausible residual bias and confounding) and the corresponding certainty (high quality, moderate quality, low quality and very low quality).[101] In contrast, if these SRs did not report the certainty of evidence, we will evaluate the overall quality of summary of evidence by the GRADE methodology.

Assessment and interpretation of clinical relevance

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

We propose comparing the continuous pooled effects with 95% CI from each meta-analysis to the MCID. With the increasing publication of MCID measurements involving different outcomes in musculoskeletal disorders, [102-105] there may be overlap. Hence, we will search and select the MCID that most closely resemble the outcomes and participants in electronic databases corresponding to our search strategy (e.g., MEDLINE, Embase, ISI Web of Science). Priority consideration will be given to the MCID determined through anchor-based methods. The MCID described as percentage change from baseline for outcomes will not be considered since this method may not be suitable for statistical analysis.[106] If the included MCID is appropriate, the pooled effects reported in MD will be directly compared to it. The pooled effects reported in SMD will not be compared to the MCID as various lumped scales may lead to substantial uncertainty. Nevertheless, when the pooled effects reported in SMD is greater than 0.5 (medium effect size), we will consider the difference between KT and other interventions as the MCID.[55,93] If the appropriate MCID is not available, we will select and use the standard deviation for distribution-based calculation. [55,56] Details of the calculation of clinical relevance are in Supplementary File 3.

Subsequently, we will adopt the systematic method provided from Man-Son Hing et al. to determine and interpret the clinical relevance of results (Figure 1).[107] The approach focuses on four levels of clinical importance between the MCID and the pooled effects with 95% CI, as below:

1. Definite: the lower limit of the 95% CI is greater than the MCID.

2. Probable: the lower limit of the 95% CI is smaller than the MCID, but the pooled effect size is greater than the MCID.

3. Possible: the pooled effect size is smaller than the MCID, but the upper limit of the 95% CI is greater than the MCID.

4. Definitely not: the upper limit of the 95% CI is smaller than the MCID.

Evidence mapping of findings

To provide credible evidence maps related to KT, we will summarise the evidence from the SRs and create user-friendly matrices of the relationship between effectiveness (positive effect, no effect, and negative effect) and outcomes. Then, we will grade the strength of evidence into five levels (convincing, highly suggestive, suggestive, weak, and non-significant evidence).[108-110] For the SRs without meta-analysis, we will evaluate the strength of evidence of positive or negative effects using the binomial test. This test (null hypothesis is equal to 0.5) will be applied to detect whether KT has a true effect.[90] For the SRs with meta-analysis, the strength of evidence will be assessed through strict criteria (e.g., number of participants and statistical significance). We will calculate the 95% prediction interval from the primary study specific data that corresponds to the SRs for outcomes. We plan to examine the excess of statistically

significant bias by detecting whether the number of observed nominally significant studies differs from the expected number of research with significant results.[111] Details of the classification criteria for strength of evidence are in Table 2.

Type of systematic review	Strength of evidence	Description		
Systematic reviews with	Class I: convincing	Number of included participants>1000;		
meta-analysis	evidence	statistical significance at P<10 ⁻⁶ ; no		
		large heterogeneity (I-square<50%);		
		95% prediction interval not including		
		null value; no small-study effects; no		
		excess significance bias		
	Class II: highly	Number of included participants>1000;		
	suggestive evidence	statistical significance at P<10 ⁻⁶ ; largest		
		study significant		
	Class III: suggestive	Number of included participants>1000;		
	evidence	statistical significance at P<10 ⁻³		
	Class IV: weak evidence	Statistical significance at P<0.05		
	Non-significant evidence	Statistical significance at P>0.05		
Systematic reviews without	Class I: convincing	Probability of observing the evidence if		
meta-analysis	evidence	positive or negative effects are not true		
		at P<0.05		
	Class IV: weak evidence	Probability of observing the evidence if		
		positive or negative effects are not true		
		at P>0.05		
	Non-significant evidence	Evidence of no effect observed		

Table 2 Classification criteria of strength of evidence.

Strategies for evidence synthesis

We will report the overview following the Preferred Reporting items for Overviews of Reviews (PRIOR) statement.[112] The selection of the SRs will be reported using the PRISMA flow chart in accordance with the PRISMA-S guideline, and the associated inter-rater reliability (Gwet's AC1 statistics) will be presented in narrative form. A list of included and excluded SRs

will be provided with descriptive explanation of reasons.

The characteristics of the included SRs regarding the relevant details of basic information, participant characteristic, search strategy, type of comparison, outcome measurement, evidence assessment tool and study conclusion will be summarised and reported in tabular form. The matrix of evidence table at the outcome level will be visually presented in the heat map graphics that informed the degree of overlap between primary RCTs in the SRs.

We will report the results concerning the quality of the RCTs (risk of bias assessed by the ROB 2.0 tool) and the quality of the SRs (reporting assessed by the SWiM guideline and the PRISMA 2020 statement, methodology assessed by the AMSTAR 2, risk of bias assessed by the ROBIS tool) in tables. The final summary of evidence (the proportion of RCTs that showed any effect and the overall pooled effects) will be tabulated, along with the discussion of sensitivity to concordant or discordant results.

The effectiveness (positive, unclear, negative effect) of KT for each outcome of interest in musculoskeletal disorders will be presented accompanied by the clinical relevance and certainty of evidence using tables and figures. The visual evidence maps of evidence (the relationship between effectiveness and outcomes) with the corresponding strengths will be plotted, subgrouped by different body regions (lower extremity, upper extremity, spinal conditions, and not otherwise classified).[65]

ETHICS AND DISSEMINATION

This overview of SRs and evidence mapping does not require ethical approval, as the data will be only collected from published literature in public databases. This results will be published

- in the peer-reviewed academic journal, and relevant datasets will be preserved in the online
- 476 repository.

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

AUTHORS' CONTRIBUTIONS QM and SX, as co-first authors, made equal contributions to the study. QM, SX, FH and XZ contributed to the conception and design of the study. SX and FH designed the eligibility criteria and search strategies. QM, SX and FH developed the study quality evaluation, data extraction and analysis plan, and evidence presenting method. XZ is the study guarantor. All authors drafted the protocol and approved the final version for publication. **FUNDING STATEMENT** This work was supported by the National Natural Science Foundation of China (No. 82205245), the Natural Science Foundation of Guangdong, China (No. 2023A1515011143), the Science and Technology Program of Guangzhou, China (No. 2023A04J0421), the Teaching quality and teaching reform project of Southern Medical University in 2022 ([2022] 22), the National College Student Innovation and Entrepreneurship Training Program (No. 202212121048 and 202312121264). **ACKNOWLEDGEMENTS** Not applicable. **COMPETING INTERESTS STATEMENT** All authors have completed the ICMJE uniform disclosure form (www.icmje.org/disclosure-ofinterest/) and declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

previous three years; no other relationships or activities that could appear to have influenced the submitted work. **DATA SHARING** No additional data are available. REFERENCES [1] GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020;396:1204-22. doi:10.1016/S0140-6736(20)30925-9 [2] Gómez-Galán M, Pérez-Alonso J, Callejón-Ferre ÁJ, et al. Musculoskeletal disorders: OWAS review. Ind Health 2017;55:314-37. doi:10.2486/indhealth.2016-0191 [3] World Health Organization. Musculoskeletal health [online]. 2022. https://www.who.int/news-room/fact-sheets/detail/musculoskeletal-conditions (accessed 23 January 2024). [4] Cieza A, Causey K, Kamenov K, et al. Global estimates of the need for rehabilitation based on the Global Burden of Disease study 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2021;396:2006-17. doi:10.1016/S0140-6736(20)32340-0 [5] Chen N, Fong DYT, Wong JYH. Secular Trends in Musculoskeletal Rehabilitation Needs in 191 Countries and Territories From 1990 to 2019. JAMA Netw Open 2022;5:e2144198.

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

doi:10.1001/jamanetworkopen.2021.44198 [6] Guan SY, Zheng JX, Sam NB, et al. Global burden and risk factors of musculoskeletal disorders among adolescents and young adults in 204 countries and territories, 1990-2019. Autoimmun Rev 2023;22:103361. doi:10.1016/j.autrev.2023.103361 [7] Liu S, Wang B, Fan S, et al. Global burden of musculoskeletal disorders and attributable factors in 204 countries and territories: a secondary analysis of the Global Burden of Disease 2019 study. *BMJ Open* 2022;12:e062183. doi:10.1136/bmjopen-2022-062183 [8] Briggs AM, Cross MJ, Hoy DG, et al. Musculoskeletal Health Conditions Represent a Global Threat to Healthy Aging: A Report for the 2015 World Health Organization World Report on Ageing and Health. Gerontologist 2016;56 Suppl 2:S243-55. doi:10.1093/geront/gnw002 [9] Chen N, Fong DYT, Wong JYH. Trends in Musculoskeletal Rehabilitation Needs in China From 1990 to 2030: A Bayesian Age-Period-Cohort Modeling Study. Front Public Health 2022;10:869239. doi:10.3389/fpubh.2022.869239 [10] Bevan S. Economic impact of musculoskeletal disorders (MSDs) on work in Europe. Best Pract Res Clin Rheumatol 2015;29:356-73. doi:10.1016/j.berh.2015.08.002 [11] Dieleman JL, Cao J, Chapin A, et al. US Health Care Spending by Payer and Health Condition, 1996-2016. JAMA 2020;323:863-84. doi:10.1001/jama.2020.0734 [12] Williams A, Kamper SJ, Wiggers JH, et al. Musculoskeletal conditions may increase the risk of chronic disease: a systematic review and meta-analysis of cohort studies. BMC Med 2018;16:167. doi:10.1186/s12916-018-1151-2 [13] El-Tallawy SN, Nalamasu R, Salem GI, et al. Management of Musculoskeletal Pain: An

Update with Emphasis on Chronic Musculoskeletal Pain. Pain Ther 2021;10:181-209. 544 doi:10.1007/s40122-021-00235-2 545 [14] Øverås CK, Nilsen TIL, Søgaard K, et al. Temporal stability in the prevalence and pattern 546 of co-occurring musculoskeletal pain among people with persistent low back pain: 547 population-based data from the Norwegian HUNT Study, 1995 to 2019. Pain 548 2023;164:2812-21. doi:10.1097/j.pain.0000000000002981 549 [15] Belluzzi E, Pozzuoli A, Ruggieri P. Musculoskeletal Diseases: From Molecular Basis to 550 Therapy. Biomedicines 2023;12:32. doi:10.3390/biomedicines12010032 551 [16] Safiri S, Kolahi AA, Cross M, et al. Prevalence, Deaths, and Disability-Adjusted Life 552 553 Years Due to Musculoskeletal Disorders for 195 Countries and Territories 1990-2017. Arthritis Rheumatol 2021;73:702-14. doi:10.1002/art.41571 554 [17] Woolf AD, Erwin J, March L. The need to address the burden of musculoskeletal 555 conditions. Best Pract Res Clin Rheumatol 2012;26:183-224. 556 doi:10.1016/j.berh.2012.03.005 557 [18] Lewis R, Gómez Álvarez CB, Rayman M, et al. Strategies for optimising 558 musculoskeletal health in the 21st century. BMC Musculoskelet Disord 2019;20:164. 559 doi:10.1186/s12891-019-2510-7 560 [19] Qin Y, Li M, Han J, et al. Research hotspots and trends of Kinesio Taping from 2011 to 561 2020: a bibliometric analysis. Environ Sci Pollut Res Int 2023;30:2029-41. 562 doi:10.1007/s11356-022-22300-9 563 [20] Tran L, Makram AM, Makram OM, et al. Efficacy of Kinesio Taping Compared to Other 564 Treatment Modalities in Musculoskeletal Disorders: A Systematic Review and Meta-565

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

Analysis. Res Sports Med 2023;31:416-39. doi:10.1080/15438627.2021.1989432 [21] Kase K, Wallis J, Kase T. Clinical Therapeutic Applications of the Kinesio Taping Method: 3rd Edition. Albuquerque, NM: Kinesio Taping Association 2013:1-41. [22] Andrýsková A, Lee JH. The Guidelines for Application of Kinesiology Tape for Prevention and Treatment of Sports Injuries. *Healthcare* 2020;8:144. doi:10.3390/healthcare8020144 [23] Rahlf AL, Braumann KM, Zech A. Kinesio Taping Improves Perceptions of Pain and Function of Patients With Knee Osteoarthritis: A Randomized, Controlled Trial. J Sport Rehabil 2019;28:481-7. doi:10.1123/jsr.2017-0306 [24] Cho HY, Kim EH, Kim J, et al. Kinesio taping improves pain, range of motion, and proprioception in older patients with knee osteoarthritis: a randomized controlled trial. Am J Phys Med Rehabil 2015;94:192-200. doi:10.1097/PHM.000000000000148 [25] Safari S, Mohsenifar H, Amiri A. The immediate effect of synergistic muscles kinesio taping on function and balance of volleyball players with functional ankle instability: A randomized controlled trial. Foot 2023;57:102058. doi:10.1016/j.foot.2023.102058 [26] Ay S, Konak HE, Evcik D, et al. The effectiveness of Kinesio Taping on pain and disability in cervical myofascial pain syndrome. Rev Bras Reumatol Engl Ed 2017;57:93-9. doi:10.1016/j.rbre.2016.03.012 [27] Espí-López GV, Inglés M, Ferrando AC, et al. Effect of Kinesio taping on clinical symptoms in people with fibromyalgia: A randomized clinical trial. J Back Musculoskelet Rehabil 2019;32:561-7. doi:10.3233/BMR-171100 [28] Algahtani AS, Parveen S. Kinesio Taping as a Therapeutic Tool for Masticatory

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

Myofascial Pain Syndrome-An Insight View. Int J Environ Res Public Health 2023;20:3872. doi:10.3390/ijerph20053872 [29] Cimino SR, Beaudette SM, Brown SHM. Kinesio taping influences the mechanical behaviour of the skin of the low back: A possible pathway for functionally relevant effects. J Biomech 2018;67:150-6. doi:10.1016/j.jbiomech.2017.12.005 [30] He F, Wang X, Yu M, et al. Effects of Kinesio taping on skin deformation during knee flexion and extension: a preliminary study. BMC Musculoskelet Disord 2022;23:187. doi:10.1186/s12891-022-05148-5 [31] Kirmizigil B, Chauchat JR, Yalciner O, et al. The Effectiveness of Kinesio Taping in Recovering From Delayed Onset Muscle Soreness: A Crossover Study. J Sport Rehabil 2019;29:385-93. doi:10.1123/jsr.2018-0389 [32] Liu K, Duan Z, Chen L, et al. Short-Term Effect of Different Taping Methods on Local Skin Temperature in Healthy Adults. Front Physiol 2020;11:488. doi:10.3389/fphys.2020.00488 [33] Lam J, Chan P, Constantinou M, et al. Personal belief on elastic tape and tape tension affect perceived performance, but not muscle activity and endurance. *Physiother Theory* Pract 2023;39:1-7. doi:10.1080/09593985.2023.2172703 [34] Au IPH, Fan PCP, Lee WY, et al. Effects of Kinesio tape in individuals with lateral epicondylitis: A deceptive crossover trial. *Physiother Theory Pract* 2017;33:914-9. doi:10.1080/09593985.2017.1359871 [35] Mak DN, Au IP, Chan M, et al. Placebo effect of facilitatory Kinesio tape on muscle activity and muscle strength. Physiother Theory Pract 2019;35:157-62.

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

doi:10.1080/09593985.2018.1441936 [36] Chinese expert consensus group of clinical application of kinesio taping. Clinical application of kinesio taping in China: Expert consensus. Chinese Journal of Physical Medicine and Rehabilitation 2021;43:97-108. doi:10.3760/cma.j.issn.0254-1424.2021.02.001 [37] Ramírez-Vélez R, Hormazábal-Aguayo I, Izquierdo M, et al. Effects of kinesio taping alone versus sham taping in individuals with musculoskeletal conditions after intervention for at least one week: a systematic review and meta-analysis. *Physiotherapy* 2019;105:412-20. doi:10.1016/j.physio.2019.04.001 [38] Parreira Pdo C, Costa Lda C, Hespanhol LC Jr, et al. Current evidence does not support the use of Kinesio Taping in clinical practice: a systematic review. J Physiother 2014;60:31-9. doi:10.1016/j.jphys.2013.12.008 [39] Kalron A, Bar-Sela S. A systematic review of the effectiveness of Kinesio Taping--fact or fashion?. Eur J Phys Rehabil Med 2013;49:699-709. [40] Morris D, Jones D, Ryan H, et al. The clinical effects of Kinesio® Tex taping: A systematic review. Physiother Theory Pract 2013;29:259-70. doi:10.3109/09593985.2012.731675 [41] Landesa-Piñeiro L, Leirós-Rodríguez R. Physiotherapy treatment of lateral epicondylitis: A systematic review. J Back Musculoskelet Rehabil 2022;35:463-77. doi:10.3233/BMR-210053 [42] George CE, Heales LJ, Stanton R, et al. Sticking to the facts: A systematic review of the effects of therapeutic tape in lateral epicondylalgia. Phys Ther Sport 2019;40:117-27.

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

doi:10.1016/j.ptsp.2019.08.011 [43] Gianola S, Iannicelli V, Fascio E, et al. Kinesio taping for rotator cuff disease. *Cochrane* Database Syst Rev 2021;8:CD012720. doi:10.1002/14651858.CD012720.pub2 [44] Ghozy S, Dung NM, Morra ME, et al. Efficacy of kinesio taping in treatment of shoulder pain and disability: a systematic review and meta-analysis of randomised controlled trials. Physiotherapy 2020;107:176-88. doi:10.1016/j.physio.2019.12.001 [45] Celik D, Karaborklu Argut S, Coban O, et al. The clinical efficacy of kinesio taping in shoulder disorders: a systematic review and meta analysis. Clin Rehabil 2020;34:723-40. doi:10.1177/0269215520917747 [46] Pan L, Li Y, Gao L, et al. Effects of Kinesio Taping for Chronic Nonspecific Low Back Pain: A Systematic Review and Meta-analysis. *Altern Ther Health Med* 2023;29:68-76. [47] Sheng Y, Duan Z, Qu Q, et al. Kinesio taping in treatment of chronic non-specific low back pain: a systematic review and meta-analysis. J Rehabil Med 2019;51:734-40. doi:10.2340/16501977-2605 [48] Luz Júnior MAD, Almeida MO, Santos RS, et al. Effectiveness of Kinesio Taping in Patients With Chronic Nonspecific Low Back Pain: A Systematic Review With Metaanalysis. Spine 2019;44:68-78. doi:10.1097/BRS.000000000002756 [49] Melese H, Alamer A, Hailu Temesgen M, et al. Effectiveness of Kinesio Taping on the Management of Knee Osteoarthritis: A Systematic Review of Randomized Controlled Trials. J Pain Res 2020;13:1267-76. doi:10.2147/JPR.S249567 [50] Wu H, Yao R, Wu J, et al. Does kinesio taping plus exercise improve pain and function in patients with knee osteoarthritis?: A systematic review and meta-analysis of randomized

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674

675

controlled trials. Front Physiol 2022;13:961264. doi:10.3389/fphys.2022.961264 [51] Ouyang JH, Chang KH, Hsu WY, et al. Non-elastic taping, but not elastic taping, provides benefits for patients with knee osteoarthritis: systemic review and metaanalysis. Clin Rehabil 2018;32:3-17. doi:10.1177/0269215517717307 [52] Vanti C, Bertozzi L, Gardenghi I, et al. Effect of taping on spinal pain and disability: systematic review and meta-analysis of randomized trials. *Phys Ther* 2015;95:493-506. doi:10.2522/ptj.20130619 [53] McGlothlin AE, Lewis RJ. Minimal clinically important difference: defining what really matters to patients. JAMA 2014;312:1342-3. doi:10.1001/jama.2014.13128 [54] Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989;10:407-15. doi:10.1016/0197-2456(89)90005-6 [55] Sedaghat AR. Understanding the Minimal Clinically Important Difference (MCID) of Patient-Reported Outcome Measures. Otolaryngol Head Neck Surg 2019;161:551-60. doi:10.1177/0194599819852604 [56] Engel L, Beaton DE, Touma Z. Minimal Clinically Important Difference: A Review of Outcome Measure Score Interpretation. Rheum Dis Clin North Am 2018;44:177-88. doi:10.1016/j.rdc.2018.01.011 [57] Angst F, Aeschlimann A, Angst J. The minimal clinically important difference raised the significance of outcome effects above the statistical level, with methodological implications for future studies. J Clin Epidemiol 2017;82:128-36. doi:10.1016/j.jclinepi.2016.11.016

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

[58] Embry TW, Piccirillo JF. Minimal Clinically Important Difference Reporting in Randomized Clinical Trials. JAMA Otolaryngol Head Neck Surg 2020;146:862-3. doi:10.1001/jamaoto.2020.1586 [59] Cheatham SW, Baker RT, Abdenour TE. Kinesiology Tape: A Descriptive Survey of Healthcare Professionals in the United States. *Int J Sports Phys Ther* 2021;16:778-96. doi:10.26603/001c.22136 [60] Hill CE, Stanton R, Heales LJ, et al. Therapeutic tape use for lateral elbow tendinopathy: A survey of Australian healthcare practitioners. *Musculoskelet Sci Pract* 2020;48:102160. doi:10.1016/j.msksp.2020.102160 [61] Hunt H, Pollock A, Campbell P, et al. An introduction to overviews of reviews: planning a relevant research question and objective for an overview. Syst Rev 2018;7:39. doi:10.1186/s13643-018-0695-8 [62] Lunny C, Brennan SE, McDonald S, et al. Toward a comprehensive evidence map of overview of systematic review methods: paper 1-purpose, eligibility, search and data extraction. Syst Rev 2017;6:231. doi:10.1186/s13643-017-0617-1 [63] Alahdab F, Murad MH. Evidence maps: a tool to guide research agenda setting. BMJ Evid Based Med 2019;24:209-11. doi:10.1136/bmjebm-2018-111137 [64] Miake-Lye IM, Hempel S, Shanman R, et al. What is an evidence map? A systematic review of published evidence maps and their definitions, methods, and products. Syst Rev 2016;5:28. doi:10.1186/s13643-016-0204-x [65] Cupler ZA, Alrwaily M, Polakowski E, et al. Taping for conditions of the musculoskeletal system: an evidence map review. Chiropr Man Therap 2020;28:52.

doi:10.1186/s12998-020-00337-2 698 [66] Saran A, White H. Evidence and gap maps: a comparison of different 699 approaches. Campbell Syst Rev 2018;14:1-38. doi:10.4073/cmdp.2018.2 700 701 [67] Lu L, Zhang Y, Ge S, et al. Evidence mapping and overview of systematic reviews of the effects of acupuncture therapies. BMJ Open 2022;12:e056803. doi:10.1136/bmjopen-702 2021-056803 703 [68] Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review 704 and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1. 705 doi:10.1186/2046-4053-4-1 706 707 [69] Pollock M, Fernandes RM, Becker LA, et al. Chapter V: Overviews of Reviews. In: Higgins JPT, Thomas J, Chandler J, et al, eds. Cochrane Handbook for Systematic 708 Reviews of Interventions version 6.4. Cochrane, 2023. Available: 709 710 www.training.cochrane.org/handbook. [70] Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated 711 guideline for reporting systematic reviews. BMJ 2021;372:n71. doi:10.1136/bmj.n71 712 [71] World Health Organization. ICD-11 for Mortality and Morbidity Statistics [online]. 2024. 713 https://icd.who.int/browse11/l-m/en (accessed 26 January 2024). 714 [72] Williamson PR, Altman DG, Bagley H, et al. The COMET Handbook: version 1.0. Trials 715 2017;18:280. doi:10.1186/s13063-017-1978-4 716 [73] Kirkham JJ, Davis K, Altman DG, et al. Core Outcome Set-STAndards for Development: 717 The COS-STAD recommendations. PLoS Med 2017;14:e1002447. 718 doi:10.1371/journal.pmed.1002447 719

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

737

738

739

740

741

[74] Black N. Patient reported outcome measures could help transform healthcare. BMJ 2013;346:f167. doi:10.1136/bmj.f167 [75] Møller MH. Patient-important outcomes and core outcome sets: increased attention needed!. Br J Anaesth 2019;122:408-10. doi:10.1016/j.bja.2019.02.007 [76] Rethlefsen ML, Kirtley S, Waffenschmidt S, et al. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews. Syst Rev 2021;10:39. doi:10.1186/s13643-020-01542-z [77] Gwet KL. Handbook of Inter-Rater Reliability: The Definitive Guide to Measuring the Extent of Agreement Among Raters: 4th ed. Gaithersburg: Advances Analytics 2014:101-28. [78] Vach W, Gerke O. Gwet's AC1 is not a substitute for Cohen's kappa - A comparison of basic properties. *MethodsX* 2023;10:102212. doi:10.1016/j.mex.2023.102212 [79] Page MJ, Sterne JAC, Boutron I, et al. ROB-ME: a tool for assessing risk of bias due to missing evidence in systematic reviews with meta-analysis. BMJ 2023;383:e076754. doi:10.1136/bmj-2023-076754 [80] Lunny C, Pieper D, Thabet P, et al. Managing overlap of primary study results across systematic reviews: practical considerations for authors of overviews of reviews. BMC Med Res Methodol 2021;21:140. doi:10.1186/s12874-021-01269-y [81] Pérez-Bracchiglione J, Meza N, Bangdiwala SI, et al. Graphical Representation of Overlap for OVErviews: GROOVE tool. Res Synth Methods 2022;13:381-8. doi:10.1002/jrsm.1557 [82] Pieper D, Antoine SL, Mathes T, et al. Systematic review finds overlapping reviews were

not mentioned in every other overview. J Clin Epidemiol 2014;67:368-75. 742 doi:10.1016/j.jclinepi.2013.11.007 743 [83] Campbell M, McKenzie JE, Sowden A, et al. Synthesis without meta-analysis (SWiM) in 744 745 systematic reviews: reporting guideline. BMJ 2020;368:16890. doi:10.1136/bmj.16890 [84] Perry R, Whitmarsh A, Leach V, et al. A comparison of two assessment tools used in 746 overviews of systematic reviews: ROBIS versus AMSTAR-2. Syst Rev 2021;10:273. 747 doi:10.1186/s13643-021-01819-x 748 [85] Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic 749 reviews that include randomised or non-randomised studies of healthcare interventions, 750 751 or both. BMJ 2017;358:j4008. doi:10.1136/bmj.j4008 752 [86] Whiting P, Savović J, Higgins JP, et al. ROBIS: A new tool to assess risk of bias in systematic reviews was developed. J Clin Epidemiol 2016;69:225-34. 753 doi:10.1016/j.jclinepi.2015.06.005 754 [87] Lorenz RC, Matthias K, Pieper D, et al. A psychometric study found AMSTAR 2 to be a 755 valid and moderately reliable appraisal tool. J Clin Epidemiol 2019;114:133-40. 756 doi:10.1016/j.jclinepi.2019.05.028 757 [88] Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in 758 randomised trials. BMJ 2019;366:14898. doi:10.1136/bmj.14898 759 760 [89] Greenland S, Senn SJ, Rothman KJ, et al. Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations. Eur J Epidemiol 2016;31:337-50. 761 doi:10.1007/s10654-016-0149-3 762

[90] McKenzie JE, Brennan SE. Chapter 12: Synthesizing and presenting findings using other

763

765

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

781

782

783

784

785

methods. In: Higgins JPT, Thomas J, Chandler J, et al, eds. Cochrane Handbook for Systematic Reviews of Interventions version 6.4. Cochrane, 2023. Available: www.training.cochrane.org/handbook. [91] Balasubramanian H, Ananthan A, Rao S, et al. Odds ratio vs risk ratio in randomized controlled trials. Postgrad Med 2015;127:359-67. doi:10.1080/00325481.2015.1022494 [92] Knol MJ, Duijnhoven RG, Grobbee DE, et al. Potential misinterpretation of treatment effects due to use of odds ratios and logistic regression in randomized controlled trials. *PLoS One* 2011;6:e21248. doi:10.1371/journal.pone.0021248 [93] Andrade C. Mean Difference, Standardized Mean Difference (SMD), and Their Use in Meta-Analysis: As Simple as It Gets. J Clin Psychiatry 2020;81:20f13681. doi:10.4088/JCP.20f13681 [94] Belur J, Tompson L, Thornton A, et al. Interrater Reliability in Systematic Review Methodology: Exploring Variation in Coder Decision-Making. Sociological Methods & Research 2021;50:837-65. doi:10.1177/0049124118799372 [95] Moja L, Fernandez del Rio MP, Banzi R, et al. Multiple systematic reviews: methods for assessing discordances of results. Intern Emerg Med 2012;7:563-8. doi:10.1007/s11739-012-0846-1 [96] Lunny C, Brennan SE, McDonald S, et al. Toward a comprehensive evidence map of overview of systematic review methods: paper 2-risk of bias assessment; synthesis, presentation and summary of the findings; and assessment of the certainty of the evidence. Syst Rev 2018;7:159. doi:10.1186/s13643-018-0784-8 [97] Lunny C, Thirugnanasampanthar SS, Kanji S, et al. How can clinicians choose between

787

788

789

790

791

792

793

794

795

796

797

798

799

800

801

802

803

804

805

806

807

conflicting and discordant systematic reviews? A replication study of the Jadad algorithm. BMC Med Res Methodol 2022;22:276. doi:10.1186/s12874-022-01750-2 [98] Guyatt GH, Oxman AD, Schünemann HJ, et al. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol 2011;64:380-2. doi:10.1016/j.jclinepi.2010.09.011 [99] Schünemann HJ, Higgins JPT, Vist GE, et al. Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, et al, eds. Cochrane Handbook for Systematic Reviews of Interventions version 6.4. Cochrane, 2023. Available: www.training.cochrane.org/handbook. [100] Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6. doi:10.1136/bmj.39489.470347.AD [101]Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011;64:401-6. doi:10.1016/j.jclinepi.2010.07.015 [102]Katajapuu N, Heinonen A, Saltychev M. Minimal clinically important difference and minimal detectable change of the World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) amongst patients with chronic musculoskeletal pain. Clin Rehabil 2020;34:1506-11. doi:10.1177/0269215520942573 [103]Benaim C, Blaser S, Léger B, et al. "Minimal clinically important difference" estimates of 6 commonly-used performance tests in patients with chronic musculoskeletal pain completing a work-related multidisciplinary rehabilitation program. BMC Musculoskelet Disord 2019;20:16. doi:10.1186/s12891-018-2382-2

809

810

811

812

813

814

815

816

817

818

819

820

821

822

823

824

825

826

827

828

829

[104] Franchignoni F, Vercelli S, Giordano A, et al. Minimal clinically important difference of the disabilities of the arm, shoulder and hand outcome measure (DASH) and its shortened version (QuickDASH). J Orthop Sports Phys Ther 2014;44:30-9. doi:10.2519/jospt.2014.4893 [105]Salaffi F, Stancati A, Silvestri CA, et al. Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale. Eur J Pain 2004;8:283-91. doi:10.1016/j.ejpain.2003.09.004 [106] Vickers AJ. The use of percentage change from baseline as an outcome in a controlled trial is statistically inefficient: a simulation study. BMC Med Res Methodol 2001;1:6. doi:10.1186/1471-2288-1-6 [107]Man-Son-Hing M, Laupacis A, O'Rourke K, et al. Determination of the clinical importance of study results. J Gen Intern Med 2002;17:469-76. doi:10.1046/j.1525-1497.2002.11111.x [108] Fusar-Poli P, Radua J. Ten simple rules for conducting umbrella reviews. Evid Based Ment Health 2018;21:95-100. doi:10.1136/ebmental-2018-300014 [109] Huang Y, Chen Z, Chen B, et al. Dietary sugar consumption and health: umbrella review. BMJ 2023;381:e071609. doi:10.1136/bmj-2022-071609 [110]Berendsen S, Berendse S, van der Torren J, et al. Cognitive behavioural therapy for the treatment of schizophrenia spectrum disorders: an umbrella review of meta-analyses of randomised controlled trials. Eclinical Medicine 2024;67:102392. doi:10.1016/j.eclinm.2023.102392 [111]Ioannidis JP, Trikalinos TA. An exploratory test for an excess of significant

findings. Clin Trials 2007;4:245-53. doi:10.1177/1740774507079441

[112]Gates M, Gates A, Pieper D, et al. Reporting guideline for overviews of reviews of healthcare interventions: development of the PRIOR statement. BMJ 2022;378:e070849.

doi:10.1136/bmj-2022-070849

FIGURE LEGENDS

835

836

837

838

Figure 1 Method of interpreting clinical relevance developed by Man-Son-Hing et al.[107] and

adapted. Dotted lines represent the clinical relevance threshold. MCID, minimal clinically

important difference.

